<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30614396</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1089-4098</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry</Title><ISOAbbreviation>Neuroscientist</ISOAbbreviation></Journal><ArticleTitle>The Expanding Clinical Universe of Polyglutamine Disease.</ArticleTitle><Pagination><StartPage>512</StartPage><EndPage>520</EndPage><MedlinePgn>512-520</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1073858418822993</ELocationID><Abstract><AbstractText>Polyglutamine (polyQ) diseases are a group of hereditary neurodegenerative disorders caused by expansion of unstable polyQ repeats in their associated disease proteins. To date, the pathogenesis of each disease remains poorly understood, and there are no effective treatments. Growing evidence has indicated that, in addition to neurodegeneration, polyQ-expanded proteins can cause a wide array of abnormalities in peripheral tissues. Indeed, polyQ-expanded proteins are ubiquitously expressed throughout the body and can affect the function of both the central nervous system (CNS) and peripheral tissues. The peripheral effects of polyQ disease proteins include muscle wasting and reduced muscle strength in patients or animal models of spinal and bulbar muscular atrophy (SBMA), Huntington's disease (HD), dentatorubral-pallidoluysian atrophy (DRPLA), and spinocerebellar ataxia type 17 (SCA17). Since skeletal muscle pathology can reflect disease progression and is more accessible for treatment than neurodegeneration in the CNS, understanding how polyQ disease proteins affect skeletal muscle will help elucidate disease mechanisms and the development of new therapeutics. In this review, we focus on important findings in terms of skeletal muscle pathology in polyQ diseases and also discuss the potential mechanisms underlying the major peripheral effects of polyQ disease proteins, as well as their therapeutic implications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Suiqiang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiao-Jiang</ForeName><Initials>XJ</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shihua</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS036232</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095181</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095279</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS101701</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuroscientist</MedlineTA><NlmUniqueID>9504819</NlmUniqueID><ISSNLinking>1073-8584</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>26700-71-0</RegistryNumber><NameOfSubstance UI="C097188">polyglutamine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C564616">Spinocerebellar Ataxia 17</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009133" MajorTopicYN="N">Muscular Atrophy</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020191" MajorTopicYN="N">Myoclonic Epilepsies, Progressive</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020754" MajorTopicYN="N">Spinocerebellar Ataxias</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CAG repeat expansion</Keyword><Keyword MajorTopicYN="N">muscle</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">peripheral pathology</Keyword><Keyword MajorTopicYN="N">protein misfolding</Keyword></KeywordList><CoiStatement>Declaration of Conflicting Interests. The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30614396</ArticleId><ArticleId IdType="mid">NIHMS1006447</ArticleId><ArticleId IdType="pmc">PMC6612477</ArticleId><ArticleId IdType="doi">10.1177/1073858418822993</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Askanas V, Engel WK. 2008. Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer&#x2019;s and Parkinson&#x2019;s disease brains. Acta Neuropathol 116:583&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635944</ArticleId><ArticleId IdType="pubmed">18974994</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR and others. 2015. Huntington disease. Nat Rev Dis Primers 1:15005.</Citation><ArticleIdList><ArticleId IdType="pubmed">27188817</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgia D, Malena A, Spinazzi M, Desbats MA, Salviati L, Russell AP and others. 2017. Increased mitophagy in the skeletal muscle of spinal and bulbar muscular atrophy patients. Hum Mol Genet 26:1087&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409076</ArticleId><ArticleId IdType="pubmed">28087734</ArticleId></ArticleIdList></Reference><Reference><Citation>Busse ME, Hughes G, Wiles CM, Rosser AE. 2008. Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington&#x2019;s disease. J Neurol 255:1534&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">19005627</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. 2015. Treating the whole body in Huntington&#x2019;s disease. Lancet Neurol 14:1135&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">26466780</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciammola A, Sassone J, Sciacco M, Mencacci NE, Ripolone M, Bizzi C and others. 2011. Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington&#x2019;s disease. Mov Disord 26:130&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3081141</ArticleId><ArticleId IdType="pubmed">20931633</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes CJ, Ling SC, Guo LT, Hung G, Tsunemi T, Ly L and others. 2014. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron 82:295&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4096235</ArticleId><ArticleId IdType="pubmed">24742458</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox H, Costin-Kelly NM, Ramani P. 2000. An established case of dentatorubral pallidoluysian atrophy (DRPLA) with unusual features on muscle biopsy. Eur J Padiatr Neurol 4:119&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10872107</ArticleId></ArticleIdList></Reference><Reference><Citation>Disatnik MH, Joshi AU, Saw NL, Shamloo M, Leavitt BR, Qi X and others. 2016. Potential biomarkers to follow the progression and treatment response of Huntington&#x2019;s disease. J Exp Med 213:2655&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5110026</ArticleId><ArticleId IdType="pubmed">27821553</ArticleId></ArticleIdList></Reference><Reference><Citation>Funakoshi H, Belluardo N, Arenas E, Yamamoto Y, Casabona A, Persson H and others. 1995. Muscle-derived neurotrophin-4 as an activity-dependent trophic signal for adult motor neurons. Science. 268(5216):1495&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7770776</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto M, Takaki E, Hayashi T, Kitaura Y, Tanaka Y, Inouye S and others. 2005. Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J Biol Chem 280:34908&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">16051598</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgetti E, Yu Z, Chua JP, Shimamura R, Zhao L, Zhu F and others. 2016. Rescue of metabolic alterations in AR113Q skeletal muscle by peripheral androgen receptor gene silencing. Cell Rep 17:125&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5076565</ArticleId><ArticleId IdType="pubmed">27681426</ArticleId></ArticleIdList></Reference><Reference><Citation>Gizatullina ZZ, Lindenberg KS, Harjes P, Chen Y, Kosinski CM, Landwehrmeyer BG and others. 2006. Low stability of Huntington muscle mitochondria against Ca2+ in R6/2 mice. Ann Neurol 59:407&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">16437579</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, Yang S, Guo J, Yan S, Gaertig MA, Li S and others. 2015. Large polyglutamine repeats cause muscle degeneration in SCA17 mice. Cell Rep 13(1):196&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598297</ArticleId><ArticleId IdType="pubmed">26387956</ArticleId></ArticleIdList></Reference><Reference><Citation>Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. 1997. Energy metabolism defects in Huntington&#x2019;s disease and effects of coenzyme Q10. Ann Neurol 41:160&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9029064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosinski CM, Schlangen C, Gellerich FN, Gizatullina Z, Deschauer M, Schiefer J and others. 2007. Myopathy as a first symptom of Huntington&#x2019;s disease in a marathon runner. Mov Disord 22:1637&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17534945</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SH, Li XJ. 2004. Huntingtin protein interactions and the pathogenesis of Huntington&#x2019;s disease. Trends Genet 20: 146&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">15036808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman AP, Shakkottai VG, Albin RL. 2018. Polyglutamine repeats in neurodegenerative diseases. Annu Rev Pathol. Aug 8 Epub ahead of print. doi:10.1146/annurev-path-mechdis-012418-012857</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-path-mechdis-012418-012857</ArticleId><ArticleId IdType="pmc">PMC6387631</ArticleId><ArticleId IdType="pubmed">30089230</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman AP, Yu Z, Murray S, Peralta R, Low A, Guo S and others. 2014. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep 7:774&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4356525</ArticleId><ArticleId IdType="pubmed">24746732</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ and others. 2000. Abnormal in vivo skeletal muscle energy metabolism in Huntington&#x2019;s disease and dentatorubropallidoluysian atrophy. Ann Neurol 48:72&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10894218</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler JP, Picchiarelli G, Dupuis L, Gonzalez De Aguilar JL. 2016. The role of skeletal muscle in amyotrophic lateral sclerosis. Brain Pathol 26:227&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">26780251</ArticleId></ArticleIdList></Reference><Reference><Citation>Malena A, Pennuto M, Tezze C, Querin G, D&#x2019;Ascenzo C, Silani V and others. 2013. Androgen-dependent impairment of myogenesis in spinal and bulbar muscular atrophy. Acta Neuropathol 126:109&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">23644820</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, Walcott J and others. 2000. CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 9:2197&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">10958659</ArticleId></ArticleIdList></Reference><Reference><Citation>Melkani GC, Trujillo AS, Ramos R, Bodmer R, Bernstein SI, Ocorr K. 2013. Huntington&#x2019;s disease induced cardiac amyloidosis is reversed by modulating protein folding and oxidative stress pathways in the Drosophila heart. PLoS Genet 9:e1004024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3868535</ArticleId><ArticleId IdType="pubmed">24367279</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP. 2009. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington&#x2019;s disease. PLoS One 4:e8025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778556</ArticleId><ArticleId IdType="pubmed">19956633</ArticleId></ArticleIdList></Reference><Reference><Citation>Monks DA, Johansen JA, Mo K, Rao P, Eagleson B, Yu Z and others. 2007. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc Natl Acad Sci U S A 104:18259&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2084330</ArticleId><ArticleId IdType="pubmed">17984063</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr HT, Zoghbi HY. 2007. Trinucleotide repeat disorders. Annu Rev Neurosci 30:575&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">17417937</ArticleId></ArticleIdList></Reference><Reference><Citation>Orth M, Cooper JM, Bates GP, Schapira AH. 2003. Inclusion formation in Huntington&#x2019;s disease R6/2 mouse muscle cultures. J Neurochem 87:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12969246</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, Bertolin C, Da Re E, Volpe M, Zara G, Pegoraro E and others. 2016. Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients. J Neurol Neurosurg Psychiatry 87:810&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4975824</ArticleId><ArticleId IdType="pubmed">26503015</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I, Stack C, Kong L, Musaro A, Adachi H, Katsuno M and others. 2009. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 63:316&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735765</ArticleId><ArticleId IdType="pubmed">19679072</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulson HL, Shakkottai VG, Clark HB, Orr HT. 2017. Polyglutamine spinocerebellar ataxias - from genes to potential treatments. Nat Rev Neurosci 18:613&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6420820</ArticleId><ArticleId IdType="pubmed">28855740</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S, Harmison GG, Meyertholen K, Pennuto M, Burnett BG, Fischbeck KH. 2009. Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum Mol Genet 18:27&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644643</ArticleId><ArticleId IdType="pubmed">18824496</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH. 2014. Increased mitochondrial fission and neuronal dysfunction in Huntington&#x2019;s disease: implications for molecular inhibitors of excessive mitochondrial fission. Drug Discov Today 19:951&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4191657</ArticleId><ArticleId IdType="pubmed">24681059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribchester RR, Thomson D, Wood NI, Hinks T, Gillingwater TH, Wishart TM and others. 2004. Progressive abnormalities in skeletal muscle and neuro-muscular junctions of transgenic mice expressing the Huntington&#x2019;s disease mutation. Eur J Neurosci 20:3092&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">15579164</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocchi A, Milioto C, Parodi S, Armirotti A, Borgia D, Pellegrini M and others. 2016. Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat diet. Acta Neuropathol 132:127&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4911374</ArticleId><ArticleId IdType="pubmed">26971100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH and others. 2014. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10(4):204&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">24614516</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P, Polanco MJ, Cristofani R, Cicardi ME, Meroni M, Galbiati M and others. 2015. Aberrant autophagic response in the muscle of a knock in mouse model of spinal and bulbar muscular atrophy. Sci Rep 5:15174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4614888</ArticleId><ArticleId IdType="pubmed">26490709</ArticleId></ArticleIdList></Reference><Reference><Citation>Saft C, Zange J, Andrich J, M&#xfc;ller K, Lindenberg K, Landwehrmeyer B and others. 2005. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington&#x2019;s disease. Mov Disord 20:674&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15704211</ArticleId></ArticleIdList></Reference><Reference><Citation>Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A. 2009. Huntington&#x2019;s disease: the current state of research with peripheral tissues. Exp Neurol 219:385&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">19460373</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F and others. 1999. Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 8:813&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">10196370</ArticleId></ArticleIdList></Reference><Reference><Citation>Saudou F, Humbert S. 2016. The biology of Huntingtin. Neuron 89(5):910&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">26938440</ArticleId></ArticleIdList></Reference><Reference><Citation>She P, Zhang Z, Marchionini D, Diaz WC, Jetton TJ, Kimball SR and others 2011. Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington&#x2019;s disease. Am J Physiol Endocrinol Metab 301:E49&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3129844</ArticleId><ArticleId IdType="pubmed">21505144</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorar&#xf9; G, D&#x2019;Ascenzo C, Polo A, Palmieri A, Baggio L, Vergani L and others. 2008. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J Neurol Sci 264:100&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17854832</ArticleId></ArticleIdList></Reference><Reference><Citation>Strand AD, Aragaki AK, Shaw D, Bird T, Holton J, Turner C and others. 2005. Gene expression in Huntington&#x2019;s disease skeletal muscle: a potential biomarker. Hum Mol Genet 14:1863&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">15888475</ArticleId></ArticleIdList></Reference><Reference><Citation>Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C and others. 2007. Expression profiling of Huntington&#x2019;s disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci 27:11758&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673215</ArticleId><ArticleId IdType="pubmed">17959817</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner C, Cooper JM, Schapira AH. 2007. Clinical correlates of mitochondrial function in Huntington&#x2019;s disease muscle. Mov Disord 22:1715&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">17557337</ArticleId></ArticleIdList></Reference><Reference><Citation>Valad&#xe3;o PA, de Arag&#xe3;o BC, Andrade JN, Magalh&#xe3;es-Gomes MP, Foureaux G, Joviano Santos JV and others. 2017. Muscle atrophy is associated with cervical spinal motoneuron loss in BACHD mouse model for Huntington&#x2019;s disease. Eur J Neurosci 45:785&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">27992085</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Burg JM, Bj&#xf6;rkqvist M, Brundin P. 2009. Beyond the brain: widespread pathology in Huntington&#x2019;s disease. Lancet Neurol 8:765&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">19608102</ArticleId></ArticleIdList></Reference><Reference><Citation>van Roon-Mom WM, Reid SJ, Faull RL, Snell RG. 2005. TATA-binding protein in neurodegenerative disease. Neuroscience 133:863&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15916858</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Chang R, Yang H, Zhao T, Hong Y, Kong HE and others. 2017. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington&#x2019;s disease. J Clin Invest 127:2719&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5490741</ArticleId><ArticleId IdType="pubmed">28628038</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Dadgar N, Albertelli M, Gruis K, Jordan C, Robins DM and others. 2006. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Invest 116:2663&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1564432</ArticleId><ArticleId IdType="pubmed">16981011</ArticleId></ArticleIdList></Reference><Reference><Citation>Zielonka D, Piotrowska I, Marcinkowski JT. 2014. Skeletal muscle pathology in Huntington&#x2019;s disease. Front Physiol 5:380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4186279</ArticleId><ArticleId IdType="pubmed">25339908</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>